EFdA-TP tetraammonium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetraammonium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetraammonium inhibits HIV-1 RT with multiple mechanisms.
性状
Solid
IC50 & Target[1][2]
HIV-1
体外研究(In Vitro)
EFdA-TP tetraammonium (0.05-10 μM; for 15 min) inhibits RT-catalyzed DNA synthesis as an ICT or DCT. EFdA-TP tetraammonium can block RT as a translocation-defective RT inhibitor that dramatically slows DNA synthesis, acting as a de facto immediate chain terminator. EFdA-TP tetraammonium can function as a delayed chain terminator, allowing incorporation of an additional dNTP before blocking DNA synthesis. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
-20°C, sealed storage, away from moisture and light In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
参考文献
[1]. Martin Markowitz, et al. 4-Ethynyl-2-fluoro-2-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor. Curr Opin HIV AIDS. 2018 Jul;13(4):294-299.[2]. Eleftherios Michailidis, et al. 4-Ethynyl-2-fluoro-2-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem. 2014 Aug 29;289(35):24533-48.